An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS)

Update Il y a 5 ans
Reference: EUCTR2007-001516-24

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is to provide long-term safety data for the use of romiplostim in thrombocytopenic subjects with myelodysplastic syndromes (MDS).


Inclusion criteria

  • Thrombocytopenic Subjects with Myelodysplastic Syndrome (MDS)